LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20359)
Download: Excel (XLSX), Comma-separated (CSV)
| Small Molecule | barcode | cell_count | frac_dead | corpse_count | cell_count_dead | row | column | agent | concentration | role | timepoint | replicate | cell_line | dead_count | fraction_dead | cell_count__time0 | dead_count__time0 | cell_count__ctrl | dead_count__ctrl | fraction_dead__ctrl | increase_fraction_dead | GRvalue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Etoposide | 180614_BG_02 | 1135 | 0.0935 | 52 | 59 | 3 | 6 | Etoposide | 0.997999808 | treatment | 72 | 1 | MCF10A-GM_1 | 111 | 0.0891 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.06909 | 0.0590 |
| Neratinib | 180614_BG_02 | 16786 | 0.0176 | 52 | 245 | 3 | 13 | Neratinib | 0.001081167 | treatment | 72 | 1 | MCF10A-GM_1 | 297 | 0.0174 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00261 | 0.9926 |
| Dasatinib | 180614_BG_04 | 6185 | 0.0396 | 71 | 177 | 3 | 5 | Dasatinib | 0.316033316 | treatment | 72 | 1 | MCF10A-GM_7 | 248 | 0.0386 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.01856 | 0.5764 |
| Etoposide | 180614_BG_04 | 10452 | 0.0192 | 99 | 104 | 3 | 22 | Etoposide | 0.099799999 | treatment | 72 | 1 | MCF10A-GM_7 | 203 | 0.0191 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00094 | 0.7829 |
| Etoposide | 180614_BG_04 | 1073 | 0.2452 | 171 | 134 | 3 | 3 | Etoposide | 0.997999808 | treatment | 72 | 1 | MCF10A-GM_7 | 305 | 0.2213 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.20134 | 0.0451 |
| Etoposide | 180614_BG_02 | 1041 | 0.1240 | 72 | 66 | 3 | 4 | Etoposide | 3.193598006 | treatment | 72 | 1 | MCF10A-GM_1 | 138 | 0.1170 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.09705 | 0.0377 |
| Dasatinib | 180614_BG_04 | 15301 | 0.0242 | 179 | 195 | 3 | 17 | Dasatinib | 0.033266667 | treatment | 72 | 1 | MCF10A-GM_8 | 374 | 0.0239 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00386 | 0.9497 |
| Dasatinib | 180614_BG_04 | 15338 | 0.0274 | 168 | 257 | 3 | 8 | Dasatinib | 0.033266667 | treatment | 72 | 1 | MCF10A-GM_7 | 425 | 0.0270 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00697 | 0.9508 |
| Dasatinib | 180614_BG_03 | 10091 | 0.0267 | 101 | 171 | 3 | 16 | Dasatinib | 0.099799999 | treatment | 72 | 1 | MCF10A-GM_4 | 272 | 0.0262 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00625 | 0.7683 |
| Etoposide | 180614_BG_04 | 15311 | 0.0253 | 162 | 230 | 3 | 12 | Etoposide | 0.033266667 | treatment | 72 | 1 | MCF10A-GM_7 | 392 | 0.0250 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00497 | 0.9500 |
| Etoposide | 180614_BG_03 | 1121 | 0.1732 | 149 | 71 | 3 | 8 | Etoposide | 0.997999808 | treatment | 72 | 1 | MCF10A-GM_4 | 220 | 0.1641 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.14406 | 0.0559 |
| Dasatinib | 180614_BG_02 | 3912 | 0.0740 | 21 | 270 | 3 | 22 | Dasatinib | 0.997999808 | treatment | 72 | 1 | MCF10A-GM_1 | 291 | 0.0692 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.04924 | 0.4158 |
| Alpelisib | 180614_BG_03 | 14548 | 0.0177 | 82 | 177 | 3 | 4 | Alpelisib | 0.316033316 | treatment | 72 | 1 | MCF10A-GM_5 | 259 | 0.0175 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00250 | 0.9268 |
| Dasatinib | 180614_BG_04 | 1838 | 0.2205 | 135 | 300 | 3 | 13 | Dasatinib | 3.193598006 | treatment | 72 | 1 | MCF10A-GM_7 | 435 | 0.1914 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.17138 | 0.1858 |
| Alpelisib | 180614_BG_03 | 16253 | 0.0172 | 65 | 216 | 3 | 13 | Alpelisib | 0.003326667 | treatment | 72 | 1 | MCF10A-GM_4 | 281 | 0.0170 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00300 | 0.9775 |
| Alpelisib | 180614_BG_03 | 5521 | 0.0329 | 104 | 81 | 3 | 11 | Alpelisib | 9.98 | treatment | 72 | 1 | MCF10A-GM_4 | 185 | 0.0324 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.01243 | 0.5350 |
| Dasatinib | 180614_BG_02 | 17360 | 0.0204 | 53 | 303 | 3 | 3 | Dasatinib | 0.003326667 | treatment | 72 | 1 | MCF10A-GM_1 | 356 | 0.0201 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00010 | 1.0084 |
| Alpelisib | 180614_BG_04 | 16160 | 0.0253 | 179 | 234 | 3 | 15 | Alpelisib | 0.099799999 | treatment | 72 | 1 | MCF10A-GM_7 | 413 | 0.0249 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00492 | 0.9749 |
| Alpelisib | 180614_BG_02 | 16563 | 0.0198 | 43 | 285 | 3 | 12 | Alpelisib | 0.00998 | treatment | 72 | 1 | MCF10A-GM_1 | 328 | 0.0194 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00058 | 0.9863 |
| Alpelisib | 180614_BG_03 | 14508 | 0.0222 | 114 | 211 | 3 | 3 | Alpelisib | 0.316033316 | treatment | 72 | 1 | MCF10A-GM_4 | 325 | 0.0219 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00192 | 0.9255 |
| Alpelisib | 180614_BG_03 | 16778 | 0.0235 | 79 | 317 | 3 | 18 | Alpelisib | 0.033266667 | treatment | 72 | 1 | MCF10A-GM_4 | 396 | 0.0231 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00306 | 0.9924 |
| Dasatinib | 180614_BG_03 | 14348 | 0.0240 | 119 | 228 | 3 | 7 | Dasatinib | 0.033266667 | treatment | 72 | 1 | MCF10A-GM_4 | 347 | 0.0236 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00362 | 0.9205 |
| Alpelisib | 180614_BG_02 | 15804 | 0.0194 | 71 | 237 | 3 | 7 | Alpelisib | 0.099799999 | treatment | 72 | 1 | MCF10A-GM_1 | 308 | 0.0191 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00088 | 0.9646 |
| Neratinib | 180614_BG_03 | 16735 | 0.0209 | 81 | 271 | 3 | 9 | Neratinib | 0.00998 | treatment | 72 | 1 | MCF10A-GM_4 | 352 | 0.0206 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00060 | 0.9912 |
| Neratinib | 180614_BG_03 | 17573 | 0.0218 | 100 | 286 | 3 | 17 | Neratinib | 0.001081167 | treatment | 72 | 1 | MCF10A-GM_4 | 386 | 0.0215 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00150 | 1.0141 |